BACKGROUND/OBJECTIVES: Colostrum is rich in immunoregulatory, antimicrobial and trophic components supporting intestinal development and function in newborns. We assessed whether bovine colostrum could enhance intestinal adaptation and function in adult short bowel syndrome (SBS) patients. SUBJECTS/METHODS: Twelve SBS patients in this randomised cross-over study received 4 weeks oral supplement of bovine colostrum or an iso-energetic and iso-proteinaceous control (2.4 MJ/d, 500 ml/day) separated by a 4-week washout period. Patients were admitted four times for 72-h periods of fluid, electrolyte and nutrient balance studies. Meals, faeces and urine were weighed, and energy, macronutrient and electrolyte contents were analysed to calculate net nutrient uptake. Body composition was measured by dual-energy X-ray absorptiometry scans, and functional tests of handgrip strength and lung functions were performed. Eight patients completed the study and were included in the analysis. RESULTS: Both supplements (colostrum and control) not only increased protein (0.96±0.42 MJ/d, P ¼ 0.004 1.03±0.44 MJ/d, P ¼ 0.003) and energy (1.46±1.02 MJ/d, P ¼ 0.005, 1.76±1.46 MJ/d, P ¼ 0.01) absorption but also absolute faecal wet weight excretions (231 ± 248 g/d, P ¼ 0.002, 319 ± 299 g/d, P ¼ 0.03), compared with baseline measurements. Both supplements improved handgrip strength (P ¼ 0.03) while only the control supplement increased lean body mass (1.12±1.33 kg, Po0.049). Colostrum was not found to be superior to the control. CONCLUSION: Intake of high-protein milk supplements increased net nutrient absorption for adult SBS patients, but at the expense of increased diarrhoea. Despite high contents of bioactive factors, colostrum did not significantly improve intestinal absorption, body composition or functional tests compared with the control.
INTRODUCTION
Short bowel syndrome (SBS) results from surgical resection, congenital defect or disease-associated loss of intestinal absorption. Short bowel patients are characterised by an inability to maintain fluid, electrolyte, trace element, vitamin or nutrient balances when fed a conventional diet. 1 A borderline separates the SBS patients with intestinal insufficiency, who manage without parenteral support, from the SBS intestinal failure patients, who depend on parental fluids, electrolytes, trace elements, vitamins and/or nutrients to maintain equilibrium, body composition, function and health. 2 Clinical treatment of SBS patients aims to improve health by maximising intestinal absorption and reducing the extent of diarrhoea and need for parenteral support. 3, 4 A key goal is to promote maximal intestinal adaptation, the process of recovery of intestinal function after injury or resection. 5 SBS patients are generally encouraged to compensate for malabsorption by implementing a degree of hyperphagia. 6, 7 Treatment strategies have included changes in diet composition, for example, high-carbohydrate and low fat-diets 8 or addition of single nutrients such as glutamine, 9 medium chain triglycerides 10 or bile acids. 11 Continuous enteral hyperalimentation has been suggested to improve macronutrient absorption, 7, 12 but the associated effects on fluid and electrolyte absorption are not clear. Hyperalimentation may be accompanied by increased faecal fluid and electrolyte losses, which could aggravate abdominal discomfort and accentuate needs for parenteral fluids, electrolytes or oral rehydration solutions. Anti-diarrhoeals 13, 14 reduce intestinal motility, whereas antisecretory agents [15] [16] [17] reduce upper GI secretions, but their effect on macronutrient absorption remains to be established. 18 Stimulation of remnant bowel adaptation with growth hormone 19 or glucagon-like peptide 2 (GLP-2) 20 has improved energy and wet weight absorption in patients with intestinal insufficiency or failure that were already well adapted, 21 probably mediated by local release of growth factors such as insulin-like growth factor 1. 22 In this context, colostrum, the first milk produced after birth in mammals, has interesting properties in addition to its normal role to stimulate growth and maturation of the newborn gut. 23 In growing SBS piglets, colostrum has been shown to improve intestinal adaptation. 24, 25 Colostrum is rich in immunoglobulins, antimicrobial peptides (lactoferrin and lactoperoxidase) and a number of other bioactive molecules and growth factors. 26 The protein content is very high (B11% v/v), and the whey proteins include a-lactalbumin, b-lactoglobulin, serum albumin, immunoglobulins, lactoferrin and peptide hormones such as growth hormone 27 and insulin-like growth factors, 28 epidermal growth factor, 29 betacellulin, 27 transforming growth factor b 30 and platelet-derived growth factor. 26 In cell-lines, animal models 31, 32 and human studies, 33 such growth factors have shown potential for proliferation and differentiation of both immature and mature cells in the gastrointestinal tract.
On this background, we hypothesised that a supplement of bovine colostrum would enhance intestinal adaptation and function in adult SBS patients compared with a standard milk-based protein control. To test our hypothesis, we evaluated effects of 4 weeks supplement of colostrum or an iso-protein-energy control to SBS patients on nutrient and fluid balances, body composition and functional indices (lung function and handgrip strength tests).
PATIENTS AND METHODS Patients
Twelve SBS patients (five females, seven males; 55.7 ± 10.7 years) were recruited based on a faecal energy excretion above 1.5 MJ as previously measured (Table 1) . Nine patients suffered from intestinal failure, five received parental nutrition, and four received fluids and electrolytes exclusively. Three patients had intestinal insufficiency and did not need parenteral support. Ten patients suffered from SBS due to Crohn's disease. None of these patients had active inflammatory bowel disease (IBD). The Ethics Committee for Medical Research in Copenhagen, Denmark approved the protocol (H-D-2008-112). Procedures were followed in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 1983. All patients signed informed consent before participation in the study.
Diets and study protocol
Colostrum was obtained from a dairy farm from cows (breed: Danish Red) at the first milking post partum (Assendrup Hovedgaard, Haslev, Denmark) with a measured energy of 534 kJ/100 ml (protein: 10.6 g/100 ml, carbohydrate 3.6 g/100 ml, fat 5.5 g/100 ml, sodium 21 mmol/l). Colostrum was tested for sufficient concentrations of immunoglobulins (Colostrumeter 290855, Kruuse, Odense, Denmark) ensuring levels of immunoglobulin above 50 mg/ml, as a positive correlation exists between protein concentration and growth factors (insulin-like growth factor-1 and 2, and transforming growth factor-b) in colostrum. 28 Colostrum was frozen at À 20 1C and sterilised (gamma irradiation 10 kGy, Sterigenics, Hørsholm, Denmark). The colostrum used was not standardised and inevitable variations between batches were not investigated further.
A nutrient-matched control was produced using semi-skimmed milk, cream and a commercial whey protein powder (Lacprodan DI 9224, ARLA Foods Ingredients, Aarhus, Denmark) with a measured energy content of 455 kJ/100 ml (protein: 10.5 g/100 ml, carbohydrate 4.8 g/100 ml, fat 3.2 g/100 ml, sodium 34 mmol/l). Patients kept track of intake using a diary designed for the study. They were randomised and given 1 week supplements by laboratory staff at a time and returned empty containers to verify compliance. Whey/casein ratio in colostrum is 75/25%, and this was similar in the control diet. A slightly higher content of carbohydrate and lower concentration of fat was present in the control diet, relative to the colostrum diet.
In this randomised, double-blind, controlled, cross-over study patients received 4 weeks oral supplement consisting of 250 ml colostrum or 250 ml control twice daily (morning and evening) in addition to their habitual diet. Patients defrosted colostrum and control on a daily basis. Test periods were separated by a washout period of at least 4 weeks, where patients only received their habitual diet. During baseline periods patients were given 500 ml of water instead of colostrum or control.
Patients were admitted four times to the hospital for 72-h nutrient, fluid and electrolyte balance studies (Figure 1 ). During first day, oral intake, nutrients and beverages were weighed and registered, and double portions were made and collected to determine the content of energy (bomb calorimetry), carbohydrate (Englyst's method), nitrogen (Kjeldahl's method) and fat (titration analyses). 16 Content of sodium and potassium (flame photometry), and calcium and magnesium (atomic absorption spectrophotometry) were also determined as previously described. 16 The patients received the same fixed diet composed at day 1 throughout their 72 h admissions. Urine and faecal output were collected and frozen at À 20 1C. The absolute intestinal absorption was calculated as the difference between oral intake and faecal output, and relative absorption was calculated as the absolute absorption divided by oral intake. All patients' medication and parental support were kept constant during the study period.
At day 1 of each admission, a general physical examination was performed, providing a medical record and measurement of handgrip strength (Jamar 5030JI Hydraulic Hand Dynanometer, Sammons Preston Rolyan, Bolingbrook, IL, USA) according to previously validated methods. 34 At day 2, a test was performed to record meal-stimulated, endogenous GLP-2 secretion. Fasting from midnight, baseline blood samples were taken at the time À 15 min at 0830 hours. Patients' individual breakfast was then served including treatment (water, colostrum or control), and blood samples were collected at 10, 20, 30, 45, 60, 90, 120 and 180 min after the meal to measure plasma GLP-2. 35 At day 3, basal metabolic rate was measured under standardised conditions by indirect calorimetry (Jaeger, Oxycon pro, Hoechberg, The Netherlands). Static and forced spirometry was performed; lung diffusion capacity for carbon monoxide (DLCO) was evaluated by single breath test (SB); and respiratory muscle strength was measured according to standards of the European Respiratory Society. [36] [37] [38] Body composition was finally measured using dual-energy X-ray absorptiometry (DEXA scanning; Norland XR-800, Cooper Surgical Company, Trumbull, CT, USA), and blood chemistry values (packed cell volume, haemoglobin, leukocytes, platelets, creatinine, glucose, potassium, magnesium, sodium, C-reactive protein, alaninetransaminase, amylase, alkaline phosphatase, D-vitamin, parathyroid hormone) were measured at the hospital laboratory according to the European standards.
Statistics
All paired data have been tested for normal distribution, and results are presented as means±standard deviations (s.d.). Two-sided Student's t-tests evaluated effects of the colostrum and control diets, compared 
Abbreviations: mb., morbus; OA, oral autonomy; PN, parental nutrition; PF, parental fluids.
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RESULTS
Complete data sets were obtained for eight patients. Two patients discontinued due to nausea and vomiting during supplementation with colostrum (patients 11 and 12). One patient left the study due to personal problems, not otherwise related to the study (patient 8). The investigators excluded one patient's data (patient 7), as major dental work impaired his ability to comply with the fixed meals during balance studies (Table 1) .
Energy and nutrient balance studies As shown in Table 2 , total energy intake was significantly higher during oral supplements (colostrum: 2.37 ± 0.77, control: 2.50±0.48 MJ/d, both Po0.0001) compared with baseline conditions, where water was supplied. Absolute energy absorption was significantly increased during both treatments (colostrum: 1.46 ± 1.02, P ¼ 0.005; control: 1.76 ± 1.46 MJ/d, P ¼ 0.01), compared with baseline conditions. No difference in absolute or relative energy absorption was seen between colostrum and control treatments. The increase in total energy intake derived mainly from increased protein intake ( Table 2 ). However, no difference in faecal carbohydrate excretion, and no differences in absolute or relative carbohydrate absorption were seen between the two treatments. As for protein and carbohydrate, fat intake was significantly higher during treatment periods (colostrum: 0.81 ± 0.94 and control: 0.57 ± 0.49 MJ/d), whereas faecal fat excretion remained the same, with no difference in absolute or relative fat absorption between the groups (Table 2) .
Wet weight and electrolytes balances In spite of keeping oral wet weight intake constant during all four admissions (Table 3) , faecal wet weight excretion significantly increased during both oral supplementations (colostrum: 231±248 g/d, P ¼ 0.04; control: 319±299 g/d, P ¼ 0.02) compared with baseline conditions. No difference in faecal wet weight excretion was seen between oral colostrum and control treatment. Relative wet weight absorption significantly decreased during control supplementation (8.6 ± 9.3%, P ¼ 0.04) compared with baseline, whereas the decrease in relation to colostrum supplementation did not reach statistical significance (6.3 ± 10.1%, P ¼ 0.12). No difference in relative wet weight absorption between colostrum and control treatment was seen (P ¼ 0.35). The increase in faecal wet weight excretion was accompanied by a significant decrease in urine output in patients receiving placebo (444±309 g/d, P ¼ 0.005) compared with baseline, and a marginal decrease during colostrum treatment (175 ± 289 g/d, P ¼ 0.13). There was no difference in urine output between colostrum and control treatment (P ¼ 0.59).
Absolute sodium absorption increased significantly during colostrum treatment compared with baseline conditions (21.4 ± 21.0 mmol/d, P ¼ 0.02), but no difference in absolute sodium absorption was seen between colostrum and control treatment (Table 3) . Likewise, relative sodium absorption did not differ between the two treatments.
All data from nutrient, fluid and electrolyte balance studies have also been analysed, with a distinction between patients with parts of colon or without parts of colon. No distinctions were found for any results, whether patients had remnants of colon or not.
Body composition, basal metabolic rate, handgrip strength and lung function Total body weight increased significantly (0.9 ± 0.3 kg, P ¼ 0.01) compared with baseline conditions for the control treatment (Table 4 ). This was accompanied by an increase in lean body mass (1.1±1.3 kg, P ¼ 0.0495) without any effects on fat mass ( À 0.03 ± 1.59 kg, P ¼ 0.95). For treatment with colostrum, no changes were observed in body weight (0.0 ± 1.6 kg, P ¼ 0.98), lean body mass ( À 0.35±1.9 kg, P ¼ 0.63) or fat mass (0.37±1.06 kg, P ¼ 0.35), relative to values at baseline. No differences were seen comparing colostrum and control.
There were no significant changes in basal metabolic rate during any of the two treatments (colostrum: 87.56±10.79 kJ/kg/d, control: 87.32±7.12 kJ/kg/d), compared with baselines (baseline 1: 86.99 ± 11.40 kJ/kg/d and baseline 2: 87.54 ± 10.72 kJ/kg/d), and no changes between the colostrum treatment and control treatment.
Handgrip strength increased during both the treatments (Table 4 ) on the dominant hand side (right hand side for all participants), relative to baseline values (colostrum 3.1 ± 3.3 kg, control diet 2.6±2.8 kg, both Po0.05), and no differences were observed between the two treatments.
Assessment of respiratory muscle strength (maximum inspiratory pressure and maximum expiratory pressure) showed normal values (Table 4) . No changes were seen during either colostrum or control treatment compared with baseline measurements, or between the two treatments.
Blood chemistry and meal-stimulated GLP-2 levels
The blood chemistry values showed no significant changes during the two treatments compared with baseline values, and no significant changes between the two treatments were observed. During supplementation with colostrum, bilirubin (2 ± 3 mmol/l, Po0.05) and phosphate (0.15 ± 0.15 mmol/l, Po0.05) concentrations increased, compared with baseline measurements, but no significant differences were seen between colostrum and control treatments. Conversely, the control diet increased plasma albumin (3 ± 3 g/l, Po0.05) and blood CO 2 (2 ± 2 mmol/l, Po0.05), and decreased ionised calcium ( À 0.04±0.03 mmol/l, Po0.05), but for none of these parameters were there any significant differences between the two treatments. Both diets increased blood urea (colostrum: 1.4±1.7 mmol/l, control: 1.9±1.6 mmol/l, both Po0.05) and urinary urea (colostrum: 81±72 mmol/d, control: 72 ± 89 mmol/d, both Po0.05), with no differences seen between the two treatments. Colostrum and control supplements added to the patients' own breakfast did not increase the circulating plasma GLP-2 compared with baseline values, and there were no differences at the various time points measured between the two treatments. No significant differences were found for the area under the curves for the four meal tests (baseline 1: 2395±459, colostrum: 2877±470, baseline 2: 2266±259, control: 3083±744).
DISCUSSION
In SBS patients, treatments aim to maximise intestinal absorption, thereby minimising diarrhoea and maintaining adequate nutrition and hydration. We hypothesised that supplementation with protein-rich milk supplements would enhance intestinal adaptation and function in adult SBS patients, and that bovine colostrum would be superior to a milk-based energy-and protein-matched control. In fact, treatment with both supplements was associated with improved nutrient absorption and improvements in functional and biochemical markers relative to baseline values, but there was no difference between the two treatments. Hence, we could not document an effect of the high concentrations of bioactive factors specifically found in colostrum.
It is possible that gastric pH is higher in newborns than in adults, including SBS patients, although five out of the eight patients received proton-pump inhibitors in this study. This may affect the degree of milk protein degradation in adult SBS patients compared with infants, and the bioactivity in the colostrum may have been eliminated before exerting its effects in the small intestine. Most studies documenting effects of colostrum in vivo have been performed in infants 39 and possibly, proteolytic degradation of colostral bioactives is lower than in adults. Furthermore, the sensitivity of the gut cells and receptors toward stimulation from colostrum may be higher in an immature and developing gut, relative to the gut in adult SBS patients especially ones that are already well adapted. Limited information is available about degradation and absorption of milk proteins in SBS patients, 40 and besides differences in pH, also gastric emptying and transit time may influence effects of specific bioactive factors. In general, SBS is characterised by rapid gastric emptying 41 and short intestinal transit time. 42 Together these factors may have resulted in a low exposure of the intestinal epithelial lining to the bioactive factors in colostrum, and thus preventing their effects on intestinal adaptation beyond the effects induced by the additional nutrient input.
The group of SBS patients included in the study was very heterogeneous regarding demographics and remnant bowel function. In a small sample size, this might result in a lower ability to detect possible effects of colostrum. An effect-heterogeneity may also exist in different subgroups within the spectrum of SBS patients. In addition, all the SBS patients included in this study were well adapted to their short bowel situation. Taken together, this could restrict the 'room for improvement' in relation to colostrum treatment. However, in a similar setting, it has been possible to demonstrate significant improvements in intestinal function employing other treatment modalities, and therefore, the effects of colostrum seem to be so modest that the clinical relevance is negligible. 20, 21, 43 In fact, two of the eight patients showed a negative value for relative improvement of intestinal absorption; the other six had improvements, though mainly minor, in the magnitude of 2-3%, and one patient improved his relative absorption with 11% from 47 to 58%.
Sodium absorption was shown to be relatively low in these patients. The large standard deviation (106 mmol/d) depicts the large heterogeneity of the SBS group including both patients with intestinal insufficiency and patients with intestinal failure.
The increase in sodium absorption in relation to colostrums treatment, compared with baseline measurements, is likely to be due to the increase in the overall sodium intake. Although the sodium content was equivalent in the control treatment, this excess sodium intake did not lead to increases in sodium absorption compared with baseline measurements in the matched control. It is not known if this finding was coincidental, but as no significance was found between the two treatments, the clinical significance is questionable.
By choosing to compare the effects of oral supplements to the effects of water, the study also evaluated effects of short-term oral hyperphagia in SBS patients. Both supplements significantly improved the absolute absorption of energy, protein and carbohydrate compared with water at baseline measurements. These apparent benefits of oral hyperphagia were, however, accompanied by increased wet weight excretion and a decreased urine production. This could deteriorate the fluid balance of the SBS patients or increase the need for parenteral fluids and thereby jeopardise overall treatment aims.
Habitual oral intake between admissions was not controlled in our study. Thus, we cannot evaluate if an increase in energy absorption was compensated by a reduction in the patients' habitual diets or lead to an increase in their physical activity. However, in patients receiving control supplement, there was a Colostrum and short bowel syndrome P Lund et al significant increase in body weight. This could be related to a better tolerance and compliance of this supplement, compared with colostrum, or to differences in the effects on appetite, where colostrum supplement could reduce regular oral intake of the habitual diet more than the control supplement. Although colostrum has been found to increase endogenous GLP-2 responses 44 in animal studies, this was not the case in our study. A previously described reduced meal-stimulated endogenous GLP-2 secretion in these patients 45 was also found in our study probably due to resection of the GLP-2 producing parts of the intestine in these patients.
Studies that measure effects of protein supplementation on body composition and muscle strength are often performed in combination with exercise. 46 In this study, protein supplements were added without controlling for exercise levels, and our SBS patients were not particularly malnourished when entering the study. This may explain why the functional effects of increased protein intake were relatively modest in our study. However, we did find a significant effect of 4 weeks high-protein supplementation on handgrip strength, a validated test to evaluate nutritional status and functional outcome in patients. 47 On the other hand, we failed to find any effects on lung function, another test to evaluate nutritional status and functional outcome in patients. 48 No improvements were detected in respiratory muscle strength (maximum inspiratory pressure and maximum expiratory pressure), but again, our patient group was not particularly malnourished, and no attempts were made to control for exercise levels, which possibly could affect markers of functional outcome.
The protein intake was high, and despite severe protein malabsorption, the absolute absorption of protein for some of the patients exceeded the limits of standard dietary recommendation of 1 g/kg body weight/day during supplementation periods. Concern regarding high protein loads has been related to possible detrimental renal effects. 49 In this study, no patients with renal impairment were included, and no changes in plasma creatinine were seen during the study. The excessive protein intake and absorption were reflected in the increased urea losses in the urine.
In conclusion, our study supports the benefits of oral proteinenergy supplements to increase protein-energy absorption in SBS patients. Even though SBS patients suffer from compromised gut function and malabsorption, and even though the patients were well adapted, had Crohns disease and thus may have a reduced adaptive capacity, it is possible to maximise absolute nutrient absorption by increasing oral intake, that is, hyperphagia. Using protein supplements in high doses did not have any negative health impacts. In fact, our SBS patients improved their muscle strength and lean body mass, even in the absence of enhanced physical exercise. However, the increased diarrhoea and reduced urine production in relation to the protein-energy supplementation may limit the use, as maintenance of fluid balance is equally crucial for SBS patients. In spite of the content of putative beneficial components, colostrum was not superior to an energyand protein-matched control in its effects on intestinal absorption, body composition or functional tests.
